PDSB

PDS Biotechnology Corporation (PDSB) | Rumor.io

PDS Biotechnology

PDSB

Attention (50-day avg)0.02%

Attention rank (50-day avg)#268

Bullish sentiment (50-day avg)87%

Price to earnings ratio-1.03

Market capitalization55.5M

Earnings per share-0.64

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-34.5M

Social

What share of all stock conversation is about PDSB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% -0.08	0.04% +0.04	0% 0

Sep 29

$PDSB's stock has been volatile, with some investors expecting a potential dip to around $0.60.
The company's asset, an HPV16-directed vaccine, has shown promise in immunologic combination with checkpoint blockade and IL-15 stimulation.
The vaccine supplies a highly specific HPV16 E6/E7 target, addressing a limitation of the Nant immune platform.

Generated by AI

Sentiment

Of the messages about PDSB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	90.91% +5.98	81.07% -5.32	87.7% +36.77	82.64% +7.24
Bearish	9.09% -5.98	18.93% +5.32	12.3% -36.77	17.36% -7.24

Bullish· Sep 24

The company's stock price has the potential to reach $211, according to a cash flow model, and is currently trading at a fair market value of $4.75, as estimated by two analysts.
The company's development stage and work on cancer vaccines are seen as a catalyst for future growth, with one user predicting a buyout or merger, even a private takeover.
The stock's price is expected to increase significantly, with one user predicting a price of $5 or higher in 2027, and another user estimating that the stock will reach $2-5 by the end of the year.

Bearish· Sep 23

The stock's performance is closely tied to the overall market, with the author stating "Entire market bites today" and "Indices on the macro are red."
The author believes the stock is overvalued, stating "dont buy a lemon or u will be crying sour grapes" and "wow fk this trash. such fkn bull shit."
The stock's price volatility is a concern, with the author noting "SSR rule triggered for tomorrow. Low of the day was 10.15% down from yesterday’s close" and "Tick Tock you negative dicks."

Generated by AI

Topics

Of the messages about PDSB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	88.89%	40.45%	48.25%
Analysts	0%	0%	24.8%	17.74%
Technical Analysis	0%	11.11%	22.13%	23.4%
Macro	0%	0%	9.66%	7.51%
Controversies	0%	0%	2.96%	2.41%
Earnings	0%	0%	0%	0.69%

Announcements· Sep 17

Patrick Soon-Shiong's investment firm, Nant Capital, has injected capital into PDS Biotechnology, with a deal worth up to $22.3M, and has joined the PDSB board with ongoing designation rights.
The partnership between PDS Biotechnology and Nant Capital is likely to lead to real integration, with a co-designed Phase 3 protocol submitted, and progress on the PDS0101 license discussion within the next 6–12 months.
The strategic fit between PDS Biotechnology's cancer vaccine and Nant Capital's Anktiva is perfect, with PDS0301 (tumor-targeted IL-12) + PDS0101 (HPV vaccine) slotting directly into Soon-Shiong's architecture of combining immune activators with targeted vaccines and other cytokines.

Technical Analysis· Sep 17

The 50-period MA has finally caught down to meet price, and the stock is currently trading in a tight coil between $0.88-0.90, with immediate resistance at $1.00-1.04.
The 50 DMA is close to passing the 200DMA up, and the MACD is strengthening, indicating potential buying pressure and a gain for the stock.
The stock's chart has been a rollercoaster, with a brief breakout and rejection, and the price is currently compressing, making it a potential accumulation area, but not yet confirmed.

Generated by AI

Community

Of the messages about PDSB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	8.51%	15.02%	11.08%	30.34%
Newcomers	91.49%	84.98%	88.92%	69.66%

Regulars· Sep 21

A Phase 2 clinical trial published in September 2026 evaluated PDS0101 (Versamune) in combination with pembrolizumab, demonstrating a 34% response rate, median progression-free survival of 5.3 months, and median overall survival of 39.3 months.
The FDA has approved PDSB's NDA, and the EMA has mentioned a MAA, with a potential market size of over $13 billion worldwide, and $6 billion in the US for metastatic colorectal cancer.
The company's CEO, PSS, has invested $22 million in PDSB and taken a seat on the board, with one regular investor encouraging others to follow suit, despite criticism from some anonymous individuals.

Newcomers· Sep 29

The newcomer is excited about PDS Biotechnology Corporation's potential to create a new paradigm for healthcare, particularly in cancer care, and believes its leader is a brilliant man who can bring about a cure.
The newcomer is optimistic about the company's future, citing the options volume and the fact that the leader, PSS, does not need money, suggesting that he sees a future with the company.
The newcomer is intrigued by the combination of PDSB's HPV16-directed vaccine and the checkpoint blockade + IL-15 stimulation, which they believe could be a highly effective immunologic combination, and notes that PDSB's PDS0101 supplies a specific target that the Nant immune platform does not inherently provide.

Generated by AI

The latest update cuts the fair value price target for PDS Biotechnology from US$5.75 to US$4.75, signaling a more conservative valuation anchor for the stock. Analysts link this change to a mix of optimism around the refocused emphasis on PDS0301 and caution about funding needs, execution risks, and the structure of the Nant led financing. As you read on, you will see how these moving pieces shape the evolving story around PDS Biotechnology and what to watch next. Stay updated as the Fair...

11d agoYahoo Finance

PDS Biotechnology Reports Initial Closing of Private Financing

PDS Biotechnology (PDSB) said Monday it has raised about $11.3 million from an initial closing of a

16d agofinance.yahoo.com

Dow Tumbles 450 Points; US Small Business Sentiment Declines In August

21d agoBenzinga

Also Discussed

Investors talking about PDSB also mention

#	Name	Attention
1	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
2	Pavmed Inc.PAVM	0%0
3	HOOK - HOOKIPA Pharma Inc.	——
4	EFTR - eFFECTOR Therapeutics, Inc.	——
5	NARI - Inari Medical, Inc.	——
6	ONCT - Oncternal Therapeutics, Inc.	——
7	MRUS - Merus N.V.	——
8	MYOV - Myovant Sciences Ltd.	——
9	DAWN - Day One Biopharmaceuticals, Inc.	——
10	MDxHealth SAMDXH	0%0

PDS Biotechnology Corporation

Healthcare
Biotechnology

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing immunotherapies that harness T cells to target cancer. Its current pipeline centers on the Versamune platform, which is designed to stimulate and direct immune responses against tumors, with programs spanning multiple oncology indications. The company also works on tumor-targeted approaches that combine immune activation with precision delivery, supporting research across head and neck, cervical, prostate, anal, breast, and other cancers. PDS Biotechnology Corporation operates as a specialist in immuno-oncology, aiming to address areas where conventional treatments may be limited. Based in Princeton, New Jersey, the company focuses on advancing current product candidates through clinical development and commercialization efforts in the biopharmaceutical market.

Website

Location

303A College Road East

Princeton, NJ, 08540

United States

Social

What share of all stock conversation is about PDSB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% -0.08	0.04% +0.04	0% 0

Sep 29

$PDSB's stock has been volatile, with some investors expecting a potential dip to around $0.60.
The company's asset, an HPV16-directed vaccine, has shown promise in immunologic combination with checkpoint blockade and IL-15 stimulation.
The vaccine supplies a highly specific HPV16 E6/E7 target, addressing a limitation of the Nant immune platform.

Generated by AI

Sentiment

Of the messages about PDSB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	90.91% +5.98	81.07% -5.32	87.7% +36.77	82.64% +7.24
Bearish	9.09% -5.98	18.93% +5.32	12.3% -36.77	17.36% -7.24

Bullish· Sep 24

The company's stock price has the potential to reach $211, according to a cash flow model, and is currently trading at a fair market value of $4.75, as estimated by two analysts.
The company's development stage and work on cancer vaccines are seen as a catalyst for future growth, with one user predicting a buyout or merger, even a private takeover.
The stock's price is expected to increase significantly, with one user predicting a price of $5 or higher in 2027, and another user estimating that the stock will reach $2-5 by the end of the year.

Bearish· Sep 23

The stock's performance is closely tied to the overall market, with the author stating "Entire market bites today" and "Indices on the macro are red."
The author believes the stock is overvalued, stating "dont buy a lemon or u will be crying sour grapes" and "wow fk this trash. such fkn bull shit."
The stock's price volatility is a concern, with the author noting "SSR rule triggered for tomorrow. Low of the day was 10.15% down from yesterday’s close" and "Tick Tock you negative dicks."

Generated by AI

Topics

Of the messages about PDSB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	88.89%	40.45%	48.25%
Analysts	0%	0%	24.8%	17.74%
Technical Analysis	0%	11.11%	22.13%	23.4%
Macro	0%	0%	9.66%	7.51%
Controversies	0%	0%	2.96%	2.41%
Earnings	0%	0%	0%	0.69%

Announcements· Sep 17

Patrick Soon-Shiong's investment firm, Nant Capital, has injected capital into PDS Biotechnology, with a deal worth up to $22.3M, and has joined the PDSB board with ongoing designation rights.
The partnership between PDS Biotechnology and Nant Capital is likely to lead to real integration, with a co-designed Phase 3 protocol submitted, and progress on the PDS0101 license discussion within the next 6–12 months.
The strategic fit between PDS Biotechnology's cancer vaccine and Nant Capital's Anktiva is perfect, with PDS0301 (tumor-targeted IL-12) + PDS0101 (HPV vaccine) slotting directly into Soon-Shiong's architecture of combining immune activators with targeted vaccines and other cytokines.

Technical Analysis· Sep 17

The 50-period MA has finally caught down to meet price, and the stock is currently trading in a tight coil between $0.88-0.90, with immediate resistance at $1.00-1.04.
The 50 DMA is close to passing the 200DMA up, and the MACD is strengthening, indicating potential buying pressure and a gain for the stock.
The stock's chart has been a rollercoaster, with a brief breakout and rejection, and the price is currently compressing, making it a potential accumulation area, but not yet confirmed.

Generated by AI

Community

Of the messages about PDSB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	8.51%	15.02%	11.08%	30.34%
Newcomers	91.49%	84.98%	88.92%	69.66%

Regulars· Sep 21

A Phase 2 clinical trial published in September 2026 evaluated PDS0101 (Versamune) in combination with pembrolizumab, demonstrating a 34% response rate, median progression-free survival of 5.3 months, and median overall survival of 39.3 months.
The FDA has approved PDSB's NDA, and the EMA has mentioned a MAA, with a potential market size of over $13 billion worldwide, and $6 billion in the US for metastatic colorectal cancer.
The company's CEO, PSS, has invested $22 million in PDSB and taken a seat on the board, with one regular investor encouraging others to follow suit, despite criticism from some anonymous individuals.

Newcomers· Sep 29

The newcomer is excited about PDS Biotechnology Corporation's potential to create a new paradigm for healthcare, particularly in cancer care, and believes its leader is a brilliant man who can bring about a cure.
The newcomer is optimistic about the company's future, citing the options volume and the fact that the leader, PSS, does not need money, suggesting that he sees a future with the company.
The newcomer is intrigued by the combination of PDSB's HPV16-directed vaccine and the checkpoint blockade + IL-15 stimulation, which they believe could be a highly effective immunologic combination, and notes that PDSB's PDS0101 supplies a specific target that the Nant immune platform does not inherently provide.

Generated by AI

PDS Biotechnology

Social

Sep 29

Bullish· Sep 24

Bearish· Sep 23

Announcements· Sep 17

Technical Analysis· Sep 17

Regulars· Sep 21

Newcomers· Sep 29

PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny

PDS Biotech Stock Surges Tuesday: What's Driving the Action?

12 Health Care Stocks Moving In Tuesday's Intraday Session

PDS Biotechnology closes $11.3M private placement led by Soon-Shiong

PDS Biotechnology Reports Initial Closing of Private Financing

Dow Tumbles 450 Points; US Small Business Sentiment Declines In August

Also Discussed

PDS Biotechnology Corporation

Company Information

Location

PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny

PDS Biotech Stock Surges Tuesday: What's Driving the Action?

12 Health Care Stocks Moving In Tuesday's Intraday Session

PDS Biotechnology closes $11.3M private placement led by Soon-Shiong

PDS Biotechnology Reports Initial Closing of Private Financing

Dow Tumbles 450 Points; US Small Business Sentiment Declines In August

Also Discussed

Social

Sep 29

Bullish· Sep 24

Bearish· Sep 23

Announcements· Sep 17

Technical Analysis· Sep 17

Regulars· Sep 21

Newcomers· Sep 29